Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 3/20 | 0.43 |
| ▸ | CTSB | P07858 | 3/20 | 0.43 |
| ▸ | PTPN1 | P18031 | 6/20 | 0.39 |
| ▸ | MDM4 | O15151 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | GRB2 | P62993 | 1/20 | 0.37 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1415070 | 1.00 | CTSL (0.43) | CTSLCTSBPTPN1MDM4TP53 | |
| SCHEMBL1410759 | 0.89 | MDM4 (0.44) | MDM4TP53 | |
| SCHEMBL1410753 | 0.89 | MDM4 (0.44) | MDM4TP53 | |
| SCHEMBL1409105 | 0.89 | CTSL (0.41) | CTSLCTSBPTPN1MDM4TP53 | |
| SCHEMBL1409102 | 0.89 | CTSL (0.41) | CTSLCTSBPTPN1MDM4TP53 | |
| SCHEMBL12601389 | 0.87 | CTSL (0.40) | CTSLCTSBPTPN1MDM4TP53 | |
| SCHEMBL1770944 | 0.84 | PTPN1 (0.41) | PTPN1MDM4TP53GRB2 | |
| SCHEMBL12509956 | 0.82 | PTPN1 (0.45) | PTPN1MDM4TP53 | |
| SCHEMBL2199171 | 0.81 | PTPN1 (0.44) | PTPN1MDM4TP53 | |
| SCHEMBL2199165 | 0.81 | PTPN1 (0.44) | PTPN1MDM4TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8614193-B2 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LIMITED (GB) | 2013-12-24 | — | — | US | disclosed |
| EP-2293846-B1 | Depsipeptides and their therapeutic use | KARUS THERAPEUTICS LTD (GB) | 2013-07-10 | — | — | EP | disclosed |
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | KARUS THERAPEUTICS LIMITED (GB) | 2011-05-12 | — | — | US | disclosed |
| EP-2293846-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | Karus Therapeutics Limited (GB) | 2011-03-16 | — | — | EP | disclosed |
| WO-2009141658-A1 | DEPSIPEPTIDES AND THEIR THERAPEUTIC USE | KARUS THERAPEUTICS LIMITED (GB) | 2009-11-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112090-A1 | Depsipeptides and Their Therapeutic Use | PRLHR, OPRD1, NPR3 | CTSL 2736/4885CTSB 3793/4885PTPN1 2258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.